Merck & Company Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Merck & Company Inc (MRK). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|
| Pharmaceutical | $13.64B 89.6% | $14.05B 89.5% | $15.61B 90.6% | $14.35B 88.9% | $14.76B 89.3% · +8.2% | $16.27B 90.7% · +15.8% |
| Animal Health | $1.59B 10.4% | $1.65B 10.5% | $1.62B 9.4% | $1.79B 11.1% | $1.78B 10.7% · +11.8% | $1.68B 9.3% · +1.8% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Operating metrics
Operating metrics are the figures a company uses to measure its own business — customer counts, stores, deliveries or the churn rate. None of them appear in the financial statements, and they often explain earlier than revenue does why revenue is moving.
| Metric | Q2 2025 | Q3 2025 | Q3 2026 |
|---|---|---|---|
| Keytruda indications approved in the U.S. | 40 | 40 | 45 +12.5% |
These metrics are not part of the financial statements; they sit in the narrative text of the filings. We read them out of the SEC filings using artificial intelligence and check every single figure against the original passage in the report; anything that is not found there verbatim is discarded. Source: SEC EDGAR (annual and quarterly reports, 10-K/10-Q).
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: November 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.